ID   NKL
AC   CVCL_0466
DR   MCCL; MCC:0000364
DR   cancercelllines; CVCL_0466
DR   Cell_Model_Passport; SIDM01880
DR   Cosmic; 1534875
DR   Cosmic; 2025324
DR   Cosmic; 2785207
DR   DepMap; ACH-001143
DR   Lonza; 145
DR   Wikidata; Q54930680
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=8599969;
RX   PubMed=10803505;
RX   PubMed=30054012;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Characteristics: IL2 dependent.
CC   Doubling time: 24-48 hours (PubMed=8599969).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: Natural killer cell; CL=CL_0000623.
DI   NCIt; C82217; Natural killer cell lymphoblastic leukemia/lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   63Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 15
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=8599969;
RA   Robertson M.J., Cochran K.J., Cameron C., Le J.-M., Tantravahi R.,
RA   Ritz J.;
RT   "Characterization of a cell line, NKL, derived from an aggressive
RT   human natural killer cell leukemia.";
RL   Exp. Hematol. 24:406-415(1996).
//
RX   PubMed=10803505; DOI=10.1038/sj.leu.2401778;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   natural killer cell leukemia-lymphoma.";
RL   Leukemia 14:777-782(2000).
//
RX   PubMed=30054012; DOI=10.1016/j.molimm.2018.07.015;
RA   Gunesch J.T., Angelo L.S., Mahapatra S., Deering R.P., Kowalko J.E.,
RA   Sleiman P., Tobias J.W., Monaco-Shawver L., Orange J.S., Mace E.M.;
RT   "Genome-wide analyses and functional profiling of human NK cell
RT   lines.";
RL   Mol. Immunol. 115:64-75(2019).
//